Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Year in Review
  • Published:

Gut microbiota in 2023

Microbiota-based biomarkers and therapeutics for cancer management

Nature Reviews Gastroenterology & Hepatology volume 21, pages 72–73 (2024)Cite this article

Subjects

New light is being shed on the interactions between the gut microbiome, cancer cell signalling and the host immune response. With this knowledge, microbiota-based approaches for improving cancer prevention, prognostication and therapy have started to materialize and will contribute to reducing the global cancer burden.

Key advances

  • A Ruminococcus bromii-driven microbiome signature that correlates with immune traits predicts overall survival of patients with colorectal cancer3.

  • Carnobacterium maltaromaticum is a potential prophylactic for colorectal cancer via enhancing intestinal vitamin D biogenesis6.

  • Downregulation of PDL2 by the gut microbiome, and specifically Coprobacillus cateniformis, is required for the efficacy of anti-PD1 or anti-PDL1 immunotherapy10.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Specific microorganisms from the human gut microbiota as emerging prognostic markers and therapeutics.

References

  1. Ashktorab, H. & Brim, H. Colorectal cancer subtyping. Nat. Rev. Cancer 22, 68–69 (2022).

    Article  CAS  PubMed  Google Scholar 

  2. Argilés, G. et al. Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 31, 1291–1305 (2020).

    Article  PubMed  Google Scholar 

  3. Roelands, J. et al. An integrated tumor, immune and microbiome atlas of colon cancer. Nat. Med. 29, 1273–1286 (2023).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Guinney, J. et al. The consensus molecular subtypes of colorectal cancer. Nat. Med. 21, 1350–1356 (2015).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Dai, Z. et al. Multi-cohort analysis of colorectal cancer metagenome identified altered bacteria across populations and universal bacterial markers. Microbiome 6, 70 (2018).

    Article  PubMed  PubMed Central  Google Scholar 

  6. Li, Q. et al. Carnobacterium maltaromaticum boosts intestinal vitamin D production to suppress colorectal cancer in female mice. Cancer Cell 41, 1450–1465.e8 (2023).

    Article  CAS  PubMed  Google Scholar 

  7. Ma, Y. et al. Association between vitamin D and risk of colorectal cancer: a systematic review of prospective studies. J. Clin. Oncol. 29, 3775–3782 (2011).

    Article  CAS  PubMed  Google Scholar 

  8. Davar, D. et al. Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients. Science 371, 595–602 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Baruch, E. N. et al. Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients. Science 371, 602–609 (2021).

    Article  CAS  PubMed  Google Scholar 

  10. Park, J. S. et al. Targeting PD-L2-RGMb overcomes microbiome-related immunotherapy resistance. Nature 617, 377–385 (2023).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

The authors’ laboratories are supported by the National Key R&D Program of China (No. 2020YFA0509200/2020YFA0509203), Research Talent Hub (RTH) of ITF scheme (ITS/177/21FP), Hong Kong RGC-Research Impact Fund (R4032-21F), Hong Kong RGC-Theme-based Research Scheme (T21-705/20-N), Hong Kong RGC-Collaborative Research Fund (C4039-19GF, C7065-18GF), Hong Kong RGC-General Research Fund (14110819, 14111621, 14116722) and CUHK Vice-Chancellor’s Discretionary Fund (CUHK PDFS2122-4S03).

Author information

Authors and Affiliations

  1. State Key Laboratory of Digestive Disease, Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong SAR, China

    William K. K. Wu & Jun Yu

  2. Department of Anaesthesia and Intensive Care, The Chinese University of Hong Kong, Hong Kong SAR, China

    William K. K. Wu

  3. Peter Hung Pain Research Institute, The Chinese University of Hong Kong, Hong Kong SAR, China

    William K. K. Wu

  4. Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong SAR, China

    Jun Yu

Authors
  1. William K. K. Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jun Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jun Yu.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wu, W.K.K., Yu, J. Microbiota-based biomarkers and therapeutics for cancer management. Nat Rev Gastroenterol Hepatol 21, 72–73 (2024). https://doi.org/10.1038/s41575-023-00879-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41575-023-00879-9

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer